Verubecestat belongs to a group of experimental Alzheimer’s drugs that prevent the formation of abnormal protein clusters in the brain, which are believed to play a role in the disease, according to the report.
Industry experts say the failed trial represents a substantial setback for the drugmaker.
“While we are disappointed that a benefit was not observed in this study, our work continues [to study the impact of] verubecestat in people with less advanced disease,” said Roger Perlmutter, MD, PhD, president of Merck Research Laboratories.
Merck expects results for a trial of verubecestat involving early-stage Alzheimer’s patients in February 2019.
More articles on supply chain:
Skin cream costs vary based on prescribing provider, study finds
Hologic to acquire Cynosure for $1.6B: 3 things to know
Former FDA commissioner shares 4 thoughts on streamlining drug approvals
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
